Takeda UK & Ireland has appointed Peter Wheatley Price as market access director, succeeding Ross Selby who moves to head the firm’s new US-based global pricing, market access and health economics oncology division.
Wheatley Price joins Takeda from GlaxoSmithKline, where he served as global market access and pricing director from 2014 to January this year, during which time he oversaw the launch of the company’s first respiratory biologic for severe asthma.
Prior to this, Wheatley Price was associate director of health economics market access and reimbursement for oncology across Europe, the Middle East and Africa at Janssen, having joined as interim head of outcomes research in 2010.
He also brings experience form Boehringer Ingelheim, where he was director of its UK Change Project, head of UK market access for prescription medicines, and held a series of marketing management positions.
Adam Zaeske, managing director of Takeda UK, said: “Owing to our ambitions to continue to deliver improved outcomes both for patients and our customers, I am delighted that we have been able to attract such a strong talent as Peter to take on such an important role in our organisation.
“It is clear to me that he shares our vision for Takeda and has both the experience and passion to help us to grow the business.”